Impact of Brexit on marketing authorisation holders – new EMA and CMDh guidance
The EC and EMA have published a Q&A document concerning the legal consequences for marketing authorisation holders of centrally authorised medicines if the UK becomes a ‘third country’ after Brexit.
The UK Government’s Brexit plan and its implications for life sciences
On January 17, 2017, Prime Minister Theresa May delivered her much anticipated speech on the UK Government’s plan for exiting the EU.
Life sciences sector spells out headline priorities for Brexit negotiations
There is no doubt that Brexit has brought uncertainty, and the sector’s two main trade bodies, the ABPI (Association of the British Pharmaceutical Industry) and BIA (BioIndustry Association) have been quick...